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Background: Studies have reported that up to 60% of individuals with schizophrenia are overweight or obese. This
study explored the relationship between obesity and cognitive performance in Chinese patients with schizophrenia.
Methods: Outpatients with schizophrenia aged 18–50 years were recruited from 10 study sites across China.
Demographic and clinical information was collected. A neuropsychological battery including tests of attention,
processing speed, learning/memory, and executive functioning was used to assess cognitive function, and these 4
individual domains were transformed into a neurocognitive composite z score. In addition, height and weight were
measured to calculate body mass index (BMI). Patients were categorized into 4 groups (underweight, normal
weight, overweight and obese) based on BMI cutoff values for Asian populations recommended by the World
Health Organization.
Results: A total number of 896 patients were enrolled into the study. Fifty-four percent of participants were
overweight or obese. A higher BMI was significantly associated with lower scores on the Wechsler Memory
Scale-Revised (WMS-R) Visual Reproduction subscale, the Wechsler Adult Intelligence Scale-Revised (WAIS-R) Digit
Symbol subscale, and the composite z score (p’s ≤ 0.024). Obese patients with schizophrenia had significantly lower
scores than normal weight patients on the Trail Making Test B, the WMS-R Visual Reproduction subscale, the WAIS
Digit Symbol subscale, and the composite z score (p’s ≤ 0.004).
Conclusions: Our study suggests that, in addition to its well established risk for various cardiometabolic conditions,
obesity is also associated with decreased cognitive function in Chinese patients with schizophrenia. Future studies
should explore if weight loss and management can improve cognitive function in obese patients who suffer from
schizophrenia.
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Patients with schizophrenia suffer from moderate to
severe cognitive impairment especially in the domains of
attention, executive functioning, memory, verbal skills,
and processing speed impairments [1,2]. Cognitive defi-
cits may represent a core pathophysiological feature of
the illness, and these deficits have been found in first
episode patients, as well as first-degree relatives of
schizophrenia patients [3,4].* Correspondence: fengcsu@yahoo.com.cn
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reproduction in any medium, provided the orObesity is common in the schizophrenia population
[5]. According to recent studies,40-60% of schizophrenia
patients are overweight or obese [6-10]. Accumulating
evidence indicates that obesity is associated with cognitive
dysfunction in non-schizophrenia populations [11-14]. A
cross-sectional study of 2,223 healthy workers aged 32 to
62 years showed that body mass index (BMI) was inde-
pendently associated with cognitive function (word-list
learning and the Digit-symbol Substitution Test) [15].
Another study in patients with bipolar disorder suggested
that overweight and obesity had a potential negative effect
on cognitive function [16]. The cognitive domains most. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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memory and executive function.
Previous studies in Asian populations have shown that
Asians have higher amounts of body fat at lower BMIs
than do Western populations, leading to a higher risk
for poorer cognitive function in Asian people than in
Western people with comparable BMIs [17]. Therefore,
there might be differential relationships between obesity
as measured by BMI and cognitive function across dif-
ferent racial or ethnic populations.
It has been well documented that overweight or obesity
is associated with decreased self-esteem and quality of life,
treatment noncompliance, and increased risk for medical
comorbidity in schizophrenia [18-20]. However, few pre-
vious studies have specifically examined the relationship
between overweight or obesity and cognitive function in
this patient population. The purpose of this study was to
investigate how obesity might be associated with cognitive
function in Chinese patients with schizophrenia.Methods
Sample
This study was part of the Early-stage Schizophrenia
Outcome Study (ESOS), which involved 10 different
sites across China [20]. Study participants were enrolled
from psychiatric outpatient clinics. The inclusion criteria
were: (1) age range between 18 to 50 years old; (2) diag-
nosis of schizophrenia or schizophreniform disorder as
determined by the Structured Clinical Interview for
DSM-IV Axis I Disorders–Clinician Version adminis-
tered by study investigators or trained staff; (3) duration
of illness ≤ 5 years; (4) in stable clinical condition (the
Positive and Negative Syndrome Scale [PANSS][21]total
scores ≤ 60); (5) on only one oral antipsychotic agent. The
exclusion criteria were: (1) a history of neurologic disor-
ders that might affect cognitive function (i.e. head injury,
cerebrovascular disease, Parkinson’s disease, Alzheimer’s
disease, seizure disorder), (2) serious or unstable medical
condition (i.e. poorly controlled diabetes or hypertension,
symptomatic coronary artery disease) or BMI ≥ 45 kg/m2;
(3) current pregnancy or breastfeeding, or history of preg-
nancy in the past 12 months; (4) substance abuse or
dependence in the past 3 months.
The study was performed in accordance with the Dec-
laration of Helsinki and approved by the Institutional
Review Board at the Second Xiangya Hospital, Chongqing
Mental Health Center, Psychiatric Hospital of Jiangxi
Province, West China Hospital, Mental Hospital of Henan
Province, Beijing Anding Hospital, Shanghai Mental
Health Center, Guangzhou Brain Hospital, Hunan Brain
Hospital, and Nanjing Brain Hospital. A written informed
consent was obtained from each subject, or his or her
legal guardians.Cognitive assessment
A cognitive battery was administered to all participants.
The battery includes the following five cognitive tests:
1) the Wechsler Adult Intelligence Scale-Revised Digit
Symbol Test [22]: this is a test of processing speed
requiring the examinee to copy symbols that match
the numbers 1 through 9 according to a key; the
number of symbols completed correctly within
120 seconds was used as the performance measure.
2) Trail Making Test, Part A and B [23]: these tests
measure processing speed and executive function,
respectively. Part A requires the subject to draw
lines connecting numbers in order; Part B requires
the subject to alternate between numbers and
letters. The time to complete each test was used as
the performance measure.
3) The Wechsler Adult Intelligence Scale-Revised Digit
Span Test [22]: this test measures attention and
working memory and requires the subject to repeat
increasingly long strings of digits forward, and then
backward. The number of correctly recalled trials in
each condition was used as the performance
measure.
4) The computerized Wisconsin Card Sorting Test
(WCST, 128-card version) [24]: this is a commonly
used test for executive function, measuring
abstraction and cognitive flexibility; the number of
categories completed and the number of
perseverative errors were used as the performance
measures.
5) The Wechsler Memory Scale-Revised Visual
Reproduction Test [25]: this is a visual learning and
memory test requiring the subject to copy and recall
abstract line drawings; the immediate recall raw
score was used as the performance measure.
The eight performance measures were grouped into
4 domains including Processing Speed (Digit
Symbol; Trail Making Test, Part A), Attention/
Working Memory (Digit Span total), Executive
Functioning (Trail Making Test, Part B; WCST
perseverative errors and categories completed), and
Visual Memory (Visual Reproduction).
All the tests were administered by raters with a
masters degree in clinical psychology; an inter-rater
reliability was established. The raters were blind to
participants’ medical status at the time of
assessment.Clinical and BMI measurements
Clinical symptoms were assessed using the Positive and
Negative Syndrome Scale (PANSS) [21] and the Mont-
gomery and Asberg Depression Scale (MADRS) [26].
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dardized procedures. BMI was calculated based on the
formula: weight in kilograms divided by height in
meters-squared (kg/m2). According to the World Health
Organization Standard classification on body mass index
for Asians [27], subjects were defined as underweight
(< 18.5 kg/m2), normal weight (18.5-22.9 kg/m2), over-
weight (23–27.4 kg/m2) and obese (≥ 27.5 kg/m2).
Statistical analysis
All analyses were conducted using the Statistical Package
for Social Sciences, version 15.0 (SPSS Inc, Chicago,
Illinois). A cognitive composite score was derived based
on the scores on the five cognitive tests. Raw scores
were first converted to standardized z-scores with the
mean of 0 and the standard deviation of 1. For domains
with more than one test, a domain z-score was createdTable 1 Demographic and clinical characteristics of the study
Characteristic Underwe
(n = 57
Age (years) 27.6 ± 8
Male, N (%) 22(38.6
Marital Status, N (%)
Married 37(64.9
Never married 16(28.1
Widowed, divorced, or separated 4(7.0)




Smoking cigarettes, N (%) 9(15.8
FBS (mg/dl) 88.8 ± 12
SBP (kPa) 15.1 ± 1
DBP (kPa) 9.9 ± 1.
DSM-IV diagnosis, N (%)
Schizophrenia 52(91.2
Schizophreniform disorder 5(8.8)
Duration of illness (years) 2.2 ± 1.
PANSS total score 47.6 ± 16
MADRS total score 5.0 ± 5.
Current medication, N (%)
Typical antipsychotics 21(31.6
Atypical antipsychotics 36(68.4
Mean daily doses of medication (clorpromazine quivalent, mg/d) 315.7 ± 10
Body mass index (kg/m2) 16.5 ± 2
aAsian BMI categories(kg/m2): underweight (< 18.5), normal weight(18.5-22.9), overw
otherwise indicated. Percentages may not sum up to 100 because of rounding.
b underweight vs overweight, p < 0.001; underweight vs obese, p < 0.001; normal w
Abbreviation: FBS, fasting blood glucose; SBP, systolic blood pressure; DBP, diastolic
Fourth Edition; PANSS, the Positive and Negative Syndrome Scale; MADRS, Montgomby calculating the mean of the z-scores for the measures
comprising the domain, then converting the mean to a
z score with a mean of zero and a standard deviation of
1. A cognitive composite score was calculated by creat-
ing a z score of the average of the 4 standardized domain
scores.
Demographic and clinical characteristics across different
BMI groups were compared using analysis of variance
(ANOVA) for continuous variables and Chi-square tests
for categorical variables. Group comparisons of cognitive
function were performed using analysis of covariance
(ANCOVA) controlling for gender. If an overall group dif-
ference was found to be significant, post hoc comparisons
were then evaluated using the Hochberg modification of
the Bonferroni correction for multiple comparisons: the
adjusted alpha for statistical significance was calculated










.5 27.1 ± 7.6 27.8 ± 6.6 27.8 ± 7.6 0.738 0.529
) 162(45.3) 203(63.6) 106(65.4) 36.683 <0.001b
3.931 0.686
) 243(67.9) 197(61.8) 106(65.4)
) 94(26.3) 103(32.3) 49(30.2)
21(5.9) 19(6.0) 7(4.3)
.8 12.5 ± 3.0 12.4 ± 2.9 12.9 ± 2.8 1.264 0.286
6.301 0.098
) 159(44.4) 113(35.4) 66(40.7)
) 199(55.6) 206(64.6) 96(59.3)
) 53(17.4) 61(19.1) 31(19.1) 3.423 0.330
.7 89.1 ± 12.0 89.3 ± 11.1 92.0 ± 18.8 0.809 0.489
.0 14.9 ± 1.2 15.0 ± 1.2 15.2 ± 1.2 2.119 0.096
0 9.8 ± 0.8 9.9 ± 0.8 10.0 ± 0.8 1.996 0.113
2.251 0.522
) 300(83.8) 273(85.6) 137(84.6)
58(16.2) 46(14.4) 25(15.4)
8 2.0 ± 1.7 2.1 ± 1.8 2.4 ± 1.8 1.706 0.164
.5 44.8 ± 14.6 44.8 ± 14.6 46.0 ± 12.9 1.325 0.265
5 5.2 ± 5.7 5.1 ± 5.5 5.3 ± 5.5 0.106 0.956
7.063 0.070
) 109(30.4) 71(22.3) 39(24.1)
) 249(69.6) 248(77.7) 123(75.9)
7.3 320.8 ± 104.4 322.0 ± 113.0 331.3 ± 115.5 0.447 0.719
.4 21.1 ± 1.9 24.9 ± 1.3 29.6 ± 2.4 2203.838 <0.001
eight (23–27.4) and obese (≥ 27.5); Data are presented as mean ± SD unless
eight vs overweight, p < 0.001; normal weight vs obese, p < 0.001;
blood pressure; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders
ery-Asberg Depression Scale.
Table 2 Partial correlations between body mass index
and cognitive function measures controlling for both age
and gender
Characteristic Body mass index p value
WAIS-R Digit Symbol −0.076 0.023
Trail Making Test A 0.016 0.641
Trail Making Test B 0.023 0.493
WCST Perseverative Errors 0.005 0.877
WCST Categories Completed −0.027 0.420
WAIS-R Digit Span −0.031 0.362
WMS-R Visual Reproduction −0.131 <0.001
Composite z score −0.082 0.018
Abbreviation: WAIS, Wechsler Adult Intelligence Scale-Revised; WCST,
Computerized Wisconsin Card Sorting Test; WMS-R, Wechsler Memory
Scale-Revised; BMI, Body mass index.
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sures were performed using partial correlation tests con-
trolling for both age and gender.
Results
Characteristics of the sample
A total of 896 patients completed the study and were
included in the data analysis. The prevalence of obesity,
overweight, and underweight were 18.1%, 35.6% and
6.4% respectively.
As shown in Table 1, there were no significant differ-
ences across different BMI groups (obesity, overweight,
normal weight and underweight) on various demographic
or clinical characteristics (p’s > 0.05) except for gender
(p < 0.001).
Correlations between BMI and cognitive measures
Correlations between BMI and various cognitive mea-
sures are showed in Table 2. Partial correlation analysis
adjusting for gender demonstrated that a higher BMI was
significantly associated with lower scores on the WAIS-RTable 3 Comparisons of cognitive function measures across d
Characteristic Underweight (n = 57) Normal weight (n
WAIS-R Digit Symbol 47.5 ± 15.8 48.3 ± 14.1
Trail Making Test A 56.6 ± 23.7 52.5 ± 24.3
Trail Making Test B 112.3 ± 59.0 106.7 ± 54.6
WCST Perseverative Errors 40.4 ± 25.8 42.7 ± 24.7
WCST Categories Completed 2.7 ± 2.2 2.5 ± 2.1
WAIS-R Digit Span 12.0 ± 3.8 12.5 ± 3.5
WMS-R Visual Reproduction 8.9 ± 2.8 9.3 ± 3.0
Composite z score 0.10 ± 0.09 0.20 ± 0.03
a Asian BMI categories(kg/m2): underweight (< 18.5), normal weight(18.5-22.9), over
bnormal weight vs obese, P = 0.001; cnormal weight vs obese, P = 0.004; dnormal we
weight vs obese, P = 0.004;
Abbreviation: WAIS, Wechsler Adult Intelligence Scale-Revised; WCST, Computerized
Body mass index.Digit Symbol test, the WMS-R Visual Reproduction test,
and the composite z score (p’s ≤ 0.024).
Comparison of cognitive measures across different BMI
groups
There were significant overall group differences in the
Trail Making Test B, the WMS-R Visual Reproduction
test, the WAIS Digit Symbol test, and the composite z
score (p’s ≤ 0.040; Table 3). Post hoc analysis revealed that
the obese group had significantly lower scores on the Trail
Making Test B, the WMS-R Visual Reproduction test, the
WAIS Digit Symbol test, and the composite z score com-
pared with the normal weight group (p’s ≤ 0.004).
Gender, obesity, and cognitive measures
There was a significant difference in BMI between males
and females (24.1 ± 3.7 and 22.8 ± 3.1, respectively, F =
29.872, p < 0.001). However, there were no significant
differences in various cognitive measures between the
two gender groups (p’s > 0.05; data not shown). Further
analysis within each gender group showed that the obese
group had significantly lower scores on the WMS-R
Visual Reproduction test, the WAIS Digit Symbol test,
and the composite z score compared with the normal
weight group (p’s ≤ 0.004; data not shown).
Antipsychotic agents, obesity and cognitive measures
There was a significant difference in BMI between patients
on typical antipsychotics and those on atypical antipsy-
chotics (22.9 ± 3.5 and 23.6 ± 3.5, respectively, F = 10.909,
p = 0.001), but there were no significant differences in vari-
ous cognitive measures between those taking typical vs.
atypical antipsychotics (p’s >0.05; data not shown).
Discussion
In this study, the percentage of overweight or obese
Chinese patients with schizophrenia was 54%, which is
higher than in the general Chinese population (43.1%) [29].ifferent BMI groupsa
= 358) Overweight (n = 319) Obese (n = 162) F p value
46.6 ± 12.8 44.0 ± 13.2 3.922 0.009b
54.9 ± 29.5 55.6 ± 27.3 0.842 0.471
114.4 ± 61.4 123.7 ± 55.5 2.784 0.040c
42.9 ± 23.7 41.6 ± 26.5 0.241 0.868
2.6 ± 2.1 2.8 ± 2.2 0.491 0.688
12.3 ± 3.1 11.9 ± 3.0 1.606 0.186
8.6 ± 2.9 8.2 ± 3.5 5.921 0.001d
0.10 ± 0.03 0.01 ± 0.05 4.365 0.005e
weight (23–27.4) and obese (≥ 27.5); Data are presented as mean ± SD.
ight vs obese, P = 0.001;normal weight vs overweight, P = 0.012 e normal
Wisconsin Card Sorting Test; WMS-R, Wechsler Memory Scale-Revised; BMI,
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demonstrated poorer cognitive performance than the nor-
mal weight patients. To our knowledge, this is the largest
study to assess the relationship between obesity and cogni-
tive function in schizophrenia. The findings of this study
suggested that obesity, in addition to being a risk factor for
various medical conditions, is associated with decreased
cognitive function in patients with schizophrenia.
The exact mechanisms linking obesity and cognitive
dysfunction remain unclear. Obesity is associated with
vascular changes, impaired insulin regulation, and re-
duced cardiovascular fitness, which all might contribute
to decreased cognitive function [30-32]. In addition,
nonvascular mechanisms linking obesity with cognitive
impairment have also been suggested [33]. Leptin, an
adipocyte-secreted protein related to obesity, may play a
role in learning and memory [34]. Interestingly, higher
levels of serum leptin appear to protect against cognitive
decline in elderly individuals, suggesting leptin resistance
as a causal pathway from obesity to cognitive impair-
ment [35]. It is also possible that schizophrenia patients
with cognitive impairment are more likely to become
obese [12]. If so, much additional work is needed to
clarify the association between BMI and worse cognitive
performance.
In our study, a higher BMI was found in patients treated
with atypical antipsychotics than in those treated with typ-
ical agents. However, there was no significant difference in
cognitive function between patients on typical vs. atypical
antipsychotics. Some atypical antipsychotic agents are as-
sociated with significant metabolic side effects; typical anti-
psychotic agents are more likely to cause other side effects
such as extrapyramidal symptoms [36]. This may be the
reason why previous studies showed atypical antipsychotic
agents are associated with better cognitive function than
typical agents in patients with schizophrenia [37].Limitations
There are several limitations to this study. First, a more
comprehensive cognitive battery might have revealed
different results. Second, the participants were not
randomly selected and the study excluded patients with
serious or unstable medical conditions; as a result, the
study sample may not be representative of individuals
with schizophrenia in China. Third, given the cross-
sectional study design, causal relationships cannot be
drawn based on our findings. Fourth, BMI may not be
the most appropriate measure to reflect obesity and
its negative impact on cardiometabolic disorders and
other health conditions [38]. Future studies using more
sophisticated techniques, such as dual-energy X-ray
absorptiometry, to measure body composition and per-
centage of fat are needed.Conclusion
Our study suggests that, in addition to its well established
risk for various cardiometabolic conditions, obesity is also
associated with worse cognitive function in Chinese
patients with schizophrenia. Future studies should explore
if weight loss and management can improve cognitive
function in obese patients who suffer from schizophrenia.
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